Literature DB >> 26617071

State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Robert W Gould1, Michael T Nedelcovych1, Xuewen Gong2, Erica Tsai2, Michael Bubser1, Thomas M Bridges1, Michael R Wood3, Mark E Duggan4, Nicholas J Brandon4, John Dunlop4, Michael W Wood4, Magnus Ivarsson5, Meredith J Noetzel1, J Scott Daniels1, Colleen M Niswender1, Craig W Lindsley3, P Jeffrey Conn1, Carrie K Jones6.   

Abstract

Accumulating evidence indicates direct relationships between sleep abnormalities and the severity and prevalence of other symptom clusters in schizophrenia. Assessment of potential state-dependent alterations in sleep architecture and arousal relative to antipsychotic-like activity is critical for the development of novel antipsychotic drugs (APDs). Recently, we reported that VU0467154, a selective positive allosteric modulator (PAM) of the M4 muscarinic acetylcholine receptor (mAChR), exhibits robust APD-like and cognitive enhancing activity in rodents. However, the state-dependent effects of VU0467154 on sleep architecture and arousal have not been examined. Using polysomnography and quantitative electroencephalographic recordings from subcranial electrodes in rats, we evaluated the effects of VU0467154, in comparison with the atypical APD clozapine and the M1/M4-preferring mAChR agonist xanomeline. VU0467154 induced state-dependent alterations in sleep architecture and arousal including delayed Rapid Eye Movement (REM) sleep onset, increased cumulative duration of total and Non-Rapid Eye Movement (NREM) sleep, and increased arousal during waking periods. Clozapine decreased arousal during wake, increased cumulative NREM, and decreased REM sleep. In contrast, xanomeline increased time awake and arousal during wake, but reduced slow wave activity during NREM sleep. Additionally, in combination with the N-methyl-d-aspartate subtype of glutamate receptor (NMDAR) antagonist MK-801, modeling NMDAR hypofunction thought to underlie many symptoms in schizophrenia, both VU0467154 and clozapine attenuated MK-801-induced elevations in high frequency gamma power consistent with an APD-like mechanism of action. These findings suggest that selective M4 PAMs may represent a novel mechanism for treating multiple symptoms of schizophrenia, including disruptions in sleep architecture without a sedative profile.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clozapine; Electroencephalography; M(4) muscarinic acetylcholine receptor; Positive allosteric modulator; VU0467154; Xanomeline

Mesh:

Substances:

Year:  2015        PMID: 26617071      PMCID: PMC4809053          DOI: 10.1016/j.neuropharm.2015.11.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  79 in total

Review 1.  Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia.

Authors:  Kwang-Hyuk Lee; Leanne M Williams; Michael Breakspear; Evian Gordon
Journal:  Brain Res Brain Res Rev       Date:  2003-01

Review 2.  High frequency oscillations in the intact brain.

Authors:  György Buzsáki; Fernando Lopes da Silva
Journal:  Prog Neurobiol       Date:  2012-03-17       Impact factor: 11.685

Review 3.  Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.

Authors:  Robert A McArthur; Julian Gray; Rudy Schreiber
Journal:  Curr Opin Investig Drugs       Date:  2010-07

4.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

5.  Electrophysiological aberrations associated with negative symptoms in schizophrenia.

Authors:  Nash N Boutros; Armida Mucci; Annarita Vignapiano; Silvana Galderisi
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 6.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

7.  Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep.

Authors:  D Riemann; H Gann; H Dressing; W E Müller; J B Aldenhoff
Journal:  Psychiatry Res       Date:  1994-03       Impact factor: 3.222

8.  EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics.

Authors:  J Roubicek; I Major
Journal:  Biol Psychiatry       Date:  1977-10       Impact factor: 13.382

9.  Effects of volatile anesthetics on the circadian rhythms of rat hippocampal acetylcholine release and locomotor activity.

Authors:  T Kikuchi; H Tan; T Mihara; K Uchimoto; D Mitsushima; K Takase; S Morita; T Goto; T Andoh; Y Kamiya
Journal:  Neuroscience       Date:  2013-02-08       Impact factor: 3.590

10.  N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia.

Authors:  Alan Anticevic; Philip R Corlett; Michael W Cole; Aleksandar Savic; Mark Gancsos; Yanqing Tang; Grega Repovs; John D Murray; Naomi R Driesen; Peter T Morgan; Ke Xu; Fei Wang; John H Krystal
Journal:  Biol Psychiatry       Date:  2014-07-31       Impact factor: 13.382

View more
  8 in total

1.  Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.

Authors:  Michael S Poslusney; James M Salovich; Michael R Wood; Bruce J Melancon; Katrina A Bollinger; Vincent B Luscombe; Alice L Rodriguez; Darren W Engers; Thomas M Bridges; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-12-18       Impact factor: 2.823

2.  Discovery of new GPCR ligands to illuminate new biology.

Authors:  Bryan L Roth; John J Irwin; Brian K Shoichet
Journal:  Nat Chem Biol       Date:  2017-10-18       Impact factor: 15.040

3.  SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs.

Authors:  Trevor C Chopko; Changho Han; Alison R Gregro; Darren W Engers; Andrew S Felts; Mike S Poslusney; Katrina A Bollinger; Ryan D Morrison; Michael Bubser; Atin Lamsal; Vincent B Luscombe; Hyekyung P Cho; Nathalie C Schnetz-Boutaud; Alice L Rodriguez; Sichen Chang; J Scott Daniels; Donald F Stec; Colleen M Niswender; Carrie K Jones; Michael R Wood; Michael W Wood; Mark E Duggan; Nicholas J Brandon; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley; Bruce J Melancon
Journal:  Bioorg Med Chem Lett       Date:  2019-06-20       Impact factor: 2.823

4.  Phenotypic profiling of mGlu7 knockout mice reveals new implications for neurodevelopmental disorders.

Authors:  Nicole M Fisher; Robert W Gould; Rocco G Gogliotti; Annalise J McDonald; Hana Badivuku; Susmita Chennareddy; Aditi B Buch; Annah M Moore; Matthew T Jenkins; W Hudson Robb; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn; Colleen M Niswender
Journal:  Genes Brain Behav       Date:  2020-04-14       Impact factor: 3.449

Review 5.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

6.  The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.

Authors:  Caterina Montani; Carola Canella; Adam J Schwarz; Jennifer Li; Gary Gilmour; Alberto Galbusera; Keith Wafford; Daniel Gutierrez-Barragan; Andrew McCarthy; David Shaw; Karen Knitowski; David McKinzie; Alessandro Gozzi; Christian Felder
Journal:  Neuropsychopharmacology       Date:  2020-12-20       Impact factor: 7.853

7.  Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates.

Authors:  Robert W Gould; Jason K Russell; Michael T Nedelcovych; Michael Bubser; Anna L Blobaum; Thomas M Bridges; Paul A Newhouse; Craig W Lindsley; P Jeffrey Conn; Michael A Nader; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2020-08-31       Impact factor: 7.853

8.  Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG.

Authors:  Kimberly M Holter; Alex D Lekander; Christina M LaValley; Elizabeth G Bedingham; Bethany E Pierce; L Paul Sands; Craig W Lindsley; Carrie K Jones; Robert W Gould
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.